Want to see TSE:DMED full AI Analyst Report?
DMED Stock Chart & Stats
C$0.05
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.05
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.25
Previous CloseN/A
Volume16.98K
Average Volume (3M)717.73K
Market Cap
C$7.24M
Enterprise ValueC$4.90
Total Cash (Recent Filing)C$293.76K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding131,559,310
10 Day Avg. Volume538,664
30 Day Avg. Volume717,725
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-21.78
Price to Sales (P/S)0.00
P/FCF Ratio-29.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtThe absence of reported debt reduces leverage and interest burden, giving management more strategic flexibility during development. For a pre-revenue biotech, lower fixed financing costs lengthen optionality for R&D and partnership negotiations without near-term solvency pressure.
AI + Medical-device FocusPositioning at the intersection of AI and medical devices targets durable structural tailwinds: digital health adoption, regulatory acceptance of AI tools, and demand for diagnostic innovation. This strategic focus can enable scalable software-enabled margins and long-term market growth if commercialized.
Equity Improved Year-over-yearAn improvement in stockholders' equity versus the prior year suggests some balance-sheet repair via financing or cost control. Over months this reduces immediate solvency risk and indicates management progress on capital structure, improving resilience compared with prior-period weakness.
Bears Say
Pre-revenue ProfileBeing pre-revenue is a structural weakness: the company cannot self-fund operations from customers and remains dependent on external financing. That lengthens the path to sustainable margins, increases dilution risk, and makes long-term viability contingent on successful product commercialization.
Accelerating Cash BurnOperating cash flow has worsened, implying accelerating cash burn and mounting near-term funding needs. With modest total assets (~$331K TTM) and negative free cash flow, management faces structural financing pressure that can force dilutive capital raises or constrain R&D/commercialization timelines.
Negative Stockholders' EquityNegative equity is a durable red flag: accumulated losses exceed invested capital, limiting borrowing capacity and deterring some strategic partners. It signals past capital erosion and creates structural constraints on access to non-dilutive funding and balance-sheet flexibility.
DiagnaMed Holdings Corp. News
DMED FAQ
What was DiagnaMed Holdings Corp.’s price range in the past 12 months?
DiagnaMed Holdings Corp. lowest stock price was C$0.03 and its highest was C$0.25 in the past 12 months.
What is DiagnaMed Holdings Corp.’s market cap?
DiagnaMed Holdings Corp.’s market cap is C$7.24M.
When is DiagnaMed Holdings Corp.’s upcoming earnings report date?
DiagnaMed Holdings Corp.’s upcoming earnings report date is Feb 02, 2027 which is in 179 days.
How were DiagnaMed Holdings Corp.’s earnings last quarter?
DiagnaMed Holdings Corp. released its earnings results on Jul 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is DiagnaMed Holdings Corp. overvalued?
According to Wall Street analysts DiagnaMed Holdings Corp.’s price is currently Overvalued.
Does DiagnaMed Holdings Corp. pay dividends?
DiagnaMed Holdings Corp. does not currently pay dividends.
What is DiagnaMed Holdings Corp.’s EPS estimate?
DiagnaMed Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiagnaMed Holdings Corp. have?
DiagnaMed Holdings Corp. has 131,559,310 shares outstanding.
What happened to DiagnaMed Holdings Corp.’s price movement after its last earnings report?
DiagnaMed Holdings Corp. reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DiagnaMed Holdings Corp.?
Currently, no hedge funds are holding shares in TSE:DMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiagnaMed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Technical Analysis
Diagnos
―
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―